Board of Directors
Dr James Cavanaugh (70)
Chairman
Dr Cavanaugh has been a member of Shire’s Board since March 24, 1997 and Chairman since May 11, 1999. Dr Cavanaugh is also Chairman of Shire’s Nomination Committee. He retired from the Board and Nomination Committee in June 2008. He is a General Partner of HealthCare Partners, a Managing Director of HealthCare Ventures, a venture capital fund devoted to healthcare, Non-Executive Chairman of Verenium Corporation, Chairman of Xanodyne Pharmaceuticals Inc. up to February 2007 after which time he remains a Board member and a Non-Executive Director of Middlebrook Pharmaceuticals Inc. He is a former President of SmithKline & French Laboratories, SmithKline Beecham Corporation’s clinical laboratory business, and Allergan International, and served as Deputy Assistant to the US President on the White House Staff.
Matthew Emmens (56)
Chief Executive Officer
Mr Emmens has been Shire’s Chief Executive Officer and a member of the Board since March 12, 2003. He is also the Chairman of Shire’s Management Committee. He succeeded Dr Cavanaugh as Non-Executive Chairman in June 2008, at which time he stepped down as Chief Executive Officer of Shire. He also serves as a Non-Executive Director of Vertex Pharmaceuticals Inc and Incyte Corporation. He began his career in international pharmaceuticals with Merck & Co, Inc. in 1974, where he held a wide range of sales, marketing and administrative positions. In 1992, he helped to establish Astra Merck, a joint venture between Merck and Astra AB of Sweden, becoming President and Chief Executive Officer. In 1999, he joined Merck KGaA and established EMD Pharmaceuticals, the company’s US prescription pharmaceutical business. He was later based in Germany as President of Merck KGaA’s US prescription pharmaceutical business and was a Board member. Mr Emmens holds a degree in Business Management from Fairleigh Dickinson University.
Angus Russell (52)
Chief Financial Officer and Executive Vice President of Global Finance
Mr Russell has been Shire’s Chief Financial Officer and a member of the Board since December 13, 1999. He is also a member of Shire’s Management Committee and is Chairman of Shire’s Corporate Responsibility Committee. He succeeded Mr Emmens as Chief Executive Officer in June 2008. He also serves as a Non-Executive Director of the City of London Investment Trust plc. Between 1980 and 1999, Mr Russell held a number of positions of increasing responsibility at ICI, Zeneca andAstraZeneca plc, including Vice President, Corporate Finance at AstraZeneca and Group Treasurer at Zeneca. Mr Russell is a chartered accountant, having qualified with Coopers & Lybrand, and is a fellow of the Association of Corporate Treasurers.
Robin Buchanan (55)
Non-Executive Director
Mr Buchanan has been a member of Shire’s Board since July 30, 2003. He is also a member of Shire’s Remuneration Committee. He also serves as a Non- Executive Director of Liberty International plc. Mr Buchanan was appointed Dean of The London Business School in July 2007. Prior to that Mr Buchanan was the Senior Partner of the UK operations and Director of the global business consultancy, Bain & Company Inc. He is a member of the Trilateral Commission. Mr Buchanan previously worked for American Express International Banking Corporation in New York, McKinsey & Company, and Deloitte & Touche, where he qualified as a chartered accountant (FCA). Mr Buchanan holds an MBA with High Distinction (Baker Scholar) from Harvard Business School.
David Kappler (60)
Non-Executive Director
Mr Kappler has been a member of Shire’s Board since April 5, 2004. He was appointed Senior Independent Director in July 2007 and was appointed Deputy Chairman and Chairman of the Nomination Committee in June 2008. He is also Chairman of Shire’s Audit, Compliance and Risk Committee and a member of the Nomination Committee. Mr Kappler also serves as the Non-Executive Chairman of Premier Foods plc and as a Non-Executive Director of Intercontinental Hotels Group plc. Mr Kappler was a Director of Camelot Group plc from 1996–2002 and of HMV Group plc from 2002–2006. Mr Kappler retired from Cadbury Schweppes plc in April 2004 after serving as Chief Financial Officer since 1995. He worked for the Cadbury Schweppes group between 1965 and 1984 and rejoined the company in 1989 following its acquisition of Trebor Group, where he was Financial Director. Mr Kappler is a fellow of the Chartered Institute of Management Accountants.
Patrick Langlois (62)
Non-Executive Director
Mr Langlois has been a member of Shire’s Board since November 11, 2005. He is also a member of Shire’s Audit, Compliance and Risk Committee and Shire’s Remuneration Committee. Mr Langlois is a Non-Executive Director of Coley Pharmaceuticals Group, Inc. and Exonhit S.A. Mr Langlois previously served as Vice Chairman of the Management Board of Aventis S.A., Strasbourg, having been Group Executive Vice President and Chief Financial Officer for several years. He also spent many years in senior financial roles with the Rhone-Poulenc Group, including three years as a member of the Executive Committee and Chief Financial Officer.
Dr Jeffrey Leiden (52)
Non-Executive Director
Dr Leiden has been a member of Shire’s Board since January 1, 2007. He has been a member of Shire’s Remuneration and Nomination Committees since July 2007. Dr Leiden served as President and Chief Operating Officer, Pharmaceutical Products Group and Chief Scientific Officer at Abbott Laboratories from 2001–2006; during this time he was also a member of the Boards of Directors of Abbott and TAP Pharmaceutical Products, Inc. Prior to joining Abbott, Dr Leiden served as the Elkan R. Blout Professor of Biological Sciences, Harvard School of Public Health and Professor of Medicine, Harvard Medical School. Prior to that, he was the Frederick H. Rawson Professor of Medicine and Pathology and Chief of the Section of Cardiology at the University of Chicago. Dr Leiden was a founder of Cardiogene, Inc., a biotechnology company specializing in cardiovascular gene therapy. Dr Leiden is currently a Managing Director at Clarus Ventures LLC.
David Mott (42)
Non-Executive Director
Mr Mott was appointed to Shire’s Board on October 31, 2007. He was also appointed to Shire’s Audit, Compliance and Risk Committee on in December 2007. Mr Mott is Chief Executive Officer and President and Vice Chairman of the Board of MedImmune, Inc, roles he has held since 2000. He joined MedImmune in 1992 and held positions of increasing responsibility including the positions of Chief Financial Officer, Chief Operating Officer and President. MedImmune was acquired by AstraZeneca (AZ) in June 2007. Mr Mott is also now serving as Executive Vice President of AZ and a member of AZ’s Senior Executive Team. Prior to joining MedImmune, he was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co., Inc. He is a member of the Board of Directors of Rib-X Pharmaceuticals and Ambit Biosciences and also serves on the Boards of Directors of the Biotechnology Industry Organization (BIO) and the Technology Council of Maryland and MdBio.
Kate Nealon (54)
Non-Executive Director
Ms Nealon has been a member of the Company’s Board since July 27, 2006. She has chaired the Company’s Remuneration Committee since July 2007 and was appointed a member of the Audit, Compliance and Risk Committee in February 2007. Ms Nealon is a Non-Executive Director of HBOS plc and Cable & Wireless plc. She is also a Senior Associate at the Judge Business School at Cambridge University. Ms Nealon was previously Group Head of Legal & Compliance at Standard Chartered plc until 2004. She is a US qualified lawyer and spent several years in her early career practising law in New York.
Dr Barry Price (64)
Non-Executive Director
Dr Price has been a member of Shire’s Board since January 16, 1996. Until July 2007 Dr Price was the Company’s Senior Non-Executive Director and a member of Shire’s Remuneration Committee and a member of Shire’s Audit, Compliance and Risk Committee. Dr Price is a member of Shire’s Nomination Committee. He also serves as Chairman of Antisoma plc and Summit plc. Dr Price worked for Glaxo for 28 years, where he held positions of increasing responsibility with the company’s research group.